CoChat

Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix

Open access
Agarwal, Sanjay K, Singh, Sukhbir S, Archer, David F, Mai, Yabing, Chwalisz, Kristof, Gordon, Keith, Surrey, Eric · 2021 · Journal of Pain Research

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: In this post hoc analysis, we evaluated the impact of elagolix on dysmenorrhea and nonmenstrual pelvic pain across menstrual period (bleeding days) and nonmenstrual (nonbleeding) days. METHODS: Data from two randomized, 6-month, placebo-controlled trials (Elaris Endometriosis (EM)-I and EM-II) of elagolix (150 mg once daily (QD) and 200 mg twice daily (BID)) in premenopausal women with moderate to severe endometriosis-associated pain (N = 1686) were pooled. Women recorded the presence of menstrual period and severity of dysmenorrhea or nonmenstrual pelvic pain in a daily electronic diary. RESULTS: At baseline, women in the placebo group and both elagolix treatment groups reported moderate or severe dysmenorrhea, on average, 81% of their menstrual period days and moderate/severe nonmenstrual pelvic pain, on average, 56% of their nonmenstrual (nonbleeding) days. Compared with placebo at month 6, elagolix-treated women had a significantly lower mean (standard deviation (SD)) percentage of menstrual period days with moderate or severe dysmenorrhea (elagolix 150 mg QD = 52.4 (38.9), p = 0.002; elagolix 200 mg BID = 38.5 (43.6), p < 0.001, placebo = 61.3 (33.7)) and a significantly lower mean (SD) percentage of nonmenstrual (nonbleeding) days with moderate or severe nonmenstrual pelvic pain (elagolix 150 mg QD = 31.1 (35.8), p < 0.001; elagolix 200 mg BID = 19.7 (29.9), p < 0.001; placebo = 35.6 (33.9)). CONCLUSION: Following 6 months of elagolix treatment, women who still menstruated had a lower proportion of menstrual period days with moderate or severe dysmenorrhea compared with placebo, demonstrating pain reduction despite continued menses. Additionally, pain did not shift from dysmenorrhea to nonmenstrual pelvic pain, as the percentage of days with moderate or severe nonmenstrual pelvic pain was also reduced for elagolix-treated women compared with placebo. TRIAL REGISTRATION: The Elaris EM-I study is registered with the US National Library of Medicine, www.ClinicalTrials.gov, NCT01620528. The Elaris EM-II study is registered with the US National Library of Medicine, www.ClinicalTrials.gov, NCT01931670. Both studies are registered with the EU Clinical Trial Register, www.clinicaltrialsregister.ed, 2011-004295-11.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/jpr.s284703

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mean number of bleeding and nonbleeding days at baseline, month 3, and month 6. Missing due to early discontinuation: month 3 (placebo, 0/726; 150 mg elagolix QD, 0/469; 200 mg BID elagolix, 1/469) and month 6 (placebo, 8/727; 150 mg elagolix QD, 2/468; 200 mg BID elagolix, 7/468). There were no statistically significant differences between either dose group and placebo for baseline age, body mass index, or mean dysmenorrhea or NMPP scores, except for the dysmenorrhea score in the elagolix 200 mg BID dose group (Elaris EM-II data, p = 0.03).
Figure 1 Mean number of bleeding and nonbleeding days at baseline, month 3, and month 6. Missing due to early discontinuation: month 3 (placebo, 0/726; 150 mg elagolix QD, 0/469; 200 mg BID elagolix, 1/469) and month 6 (placebo, 8/727; 150 mg elagolix QD, 2/468; 200 mg BID elagolix, 7/468). There were no statistically significant differences between either dose group and placebo for baseline age, body mass index, or mean dysmenorrhea or NMPP scores, except for the dysmenorrhea score in the elagolix 200 mg BID dose group (Elaris EM-II data, p = 0.03).CC BY-NC · PubMed Central
Figure 2 Mean number and mean percent of bleeding days with dysmenorrhea (A and B). Mean number and mean percent of nonbleeding days with nonmenstrual pelvic pain (C and D). p < 0.001 (***) and p < 0.01 (**) vs placebo for percent of women with “moderate or severe” or “none” regarding dysmenorrhea or nonmenstrual pelvic pain (NMPP) from a Wilcoxon rank sum test. Number of days is equal to the number of days the subject reported dysmenorrhea or NMPP as none, mild, moderate, or severe. Missing dysmenorrhea with nonmissing NMPP or missing NMPP with nonmissing dysmenorrhea are imputed as zero days. Percentage of days is equal to the number of days the subject reported dysmenorrhea or NMPP divided by the number of days she answered the e-diary, multiplied by 100. Baseline is defined as the average of the last 35 days prior to and including the first dosing date.
Figure 2 Mean number and mean percent of bleeding days with dysmenorrhea (A and B). Mean number and mean percent of nonbleeding days with nonmenstrual pelvic pain (C and D). p < 0.001 (***) and p < 0.01 (**) vs placebo for percent of women with “moderate or severe” or “none” regarding dysmenorrhea or nonmenstrual pelvic pain (NMPP) from a Wilcoxon rank sum test. Number of days is equal to the number of days the subject reported dysmenorrhea or NMPP as none, mild, moderate, or severe. Missing dysmenorrhea with nonmissing NMPP or missing NMPP with nonmissing dysmenorrhea are imputed as zero days. Percentage of days is equal to the number of days the subject reported dysmenorrhea or NMPP divided by the number of days she answered the e-diary, multiplied by 100. Baseline is defined as the average of the last 35 days prior to and including the first dosing date.CC BY-NC · PubMed Central
Figure 3 Percent of nonmenstrual pelvic pain responders by bleeding status. Responder equals reduced nonmenstrual pelvic pain and reduced or stable rescue analgesic use. p < 0.001 (***), p < 0.01 (**), and p < 0.05 (*) vs placebo using a contrast within the subgroup in the logistic regression model.
Figure 3 Percent of nonmenstrual pelvic pain responders by bleeding status. Responder equals reduced nonmenstrual pelvic pain and reduced or stable rescue analgesic use. p < 0.001 (***), p < 0.01 (**), and p < 0.05 (*) vs placebo using a contrast within the subgroup in the logistic regression model.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Ng J, Klein CE, Carter DC, Chwalisz K. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683–1691. doi:10.1210/jc.2016-3845 · DOI · Paper page

Cited by

See all 11

Metadata

Authors
Agarwal, S. K., Singh, S. S., Archer, D. F., Mai, Y., Chwalisz, K., Gordon, K., & Surrey, E.
Affiliations
  • University of California San Diego (US)
  • Ottawa Hospital Research Institute (CA)
  • Eastern Virginia Medical School (US)
  • AbbVie (United States) (US)
  • Colorado Center for Reproductive Medicine (US)
Corresponding author
Agarwal, Sanjay K
Venue
Journal of Pain Research
Published
2021-02
Volume
Volume 14
Pages
263-271
ISSN
1178-7090 (ISSN-L)
OpenAlex
W3128524842
Cited by
11
References
16
Citations by year
2026: 2 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 4
FWCI
1.94
Type
journal article
Language
en
Open access
Locations
  • Journal of Pain Research (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
Funders
  • Pfizer
  • Teva Pharmaceutical Industries
  • AbbVie
  • Radius Health
  • Bayer HealthCare
  • Shionogi
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
  • Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
Keywords
endometriosis, elagolix, dysmenorrhea, menstrual bleeding, analgesia, premenopausal women, endometriosis-associated pain, dose comparison, post hoc analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.